US Patent

US12102609 — Methods of administering solriamfetol to lactating women

Method of Use · Assigned to Axsome Malta Ltd · Expires 2042-12-30 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for reducing the risk of adverse events in infants by delaying breastfeeding after administering solriamfetol to lactating women.

USPTO Abstract

Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3693 — solriamfetol-hydrochloride
U-3693 — solriamfetol-hydrochloride

Patent Metadata

Patent number
US12102609
Jurisdiction
US
Classification
Method of Use
Expires
2042-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Axsome Malta Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.